Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors
-- Ms. Burstein bring significant experience in finance for publicly-traded biotechnology companies --
BEDFORD, MA, June 14, 2019 -- (Business Wire) -- Stoke Therapeutics, Inc., a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Jennifer Burstein to its board of directors. Ms. Burstein will join the audit committee and serve as its chair.
“Jennifer’s significant experience managing financial responsibilities for publicly-traded biotechnology companies further strengthens our board of directors,” said Edward M. Kaye, M.D., chief executive officer of Stoke Therapeutics. “We are confident that her extensive industry knowledge and deep financial background will support Stoke as the company continues to mature and we work to pioneer a new way to treat severe genetic diseases.”
Ms. Burstein most recently served as senior vice president of finance and principal financial officer at Loxo Oncology, Inc., until its acquisition by Eli Lilly and Company in January 2019. From 2006 to 2015, Ms. Burstein held roles of increasing responsibility in finance at Acorda Therapeutics, Inc., and ultimately served as vice president of finance for the company from 2010 to 2015. Before that, she worked on the finance team at Eyetech Pharmaceuticals, Inc., which is currently a subsidiary of Valeant Pharmaceuticals International, Inc. Earlier in her career, Ms. Burstein worked in the finance departments at several companies and in public accounting. She holds a B.S. in business administration and her MBA in accounting, both from the State University of New York at Buffalo, and holds a CPA license in New York.
About Stoke Therapeutics
Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50 percent of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke was launched with investments by Apple Tree Partners and has raised a total of over $130 million to date through two financing rounds. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information visit StokeTherapeutics.com and follow Stoke on Twitter @StokeTx.